洛沙坦对慢性肺心病肺动脉高压的治疗效应研究  

Clinical effects study of Losartan on pulmonary hypertension in patients with chronic pulmonary heart disease

作　　者：倪斌 叶健[2] NI Bin;YE Jian(Department of Pharmacy, Hangzhou First People’s Hospital, Hangzhou 310006, China;Department of Respiratory Medicine Hangzhou First People’s Hospital, Hangzhou 310006, China)

机构地区：[1]杭州市第一人民医院药学部,浙江杭州310006 [2]杭州市第一人民医院呼吸内科,浙江杭州310006

出　　处：《中国生化药物杂志》2017年第12期341-342,共2页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的分析洛沙坦对慢性肺心病肺动脉高压的治疗效果。方法选取杭州市第一人民医院收治的50例慢性肺心病肺动脉高压患者为研究对象。对照组给予抗感染、吸氧等常规治疗，实验组在此基础上进行洛沙坦，剂量为50mg/次。比较分析2组患者治疗前后的血管紧张素II及肺动脉压等临床指标。结果治疗前，实验组PaO2与肺动脉压分别为（59.22±5.45）mmHg与（32.20±6.23）mmHg与对照组相比，差异无统计学意义。经过对应治疗后，实验组患者肺动脉压为（22.30±4.22）mmHg显著低于对照组肺动脉压为（29.80±5.59）mmHg，差异具有统计学意义（P＜0.05）。实验组患者PaO2为（82.30±4.43）mmHg显著高于对照组PaO2（70.20±5.22）mmHg，差异具有统计学意义（P＜0.05）。实验组血管紧张素II为（93.65±5.20）pg/mL与对照组相比，差异无统计学意义。结论洛沙坦对慢性肺心病肺动脉高压的治疗效果较为理想，可显著降低患者肺动脉压，扩张血管。Objective To study clinical effects of Losartan on pulmonary hypertension in patients with chronic pulmonary heart disease.Methods50cases of chronic pulmonary heart disease and pulmonary hypertension in the Hangzhou First People’s hospital were selected as the subjects.The control group was given routine treatment of anti infection,oxygen,the experimental group was given Losartan on the basis of the control group,a dose of50mg.The clinical indicators of angiotensin II and pulmonary arterial pressure before and after treatment in two groups were compared and analyzed.Results Before treatment,the PaO2was(59.22±5.45)mmHg and pulmonary arterial pressure was(32.20±6.23)mmHg in the experimental,there was no statistical significance between the control group and the experimental group.After the corresponding treatment,the pulmonary artery pressure of the experimental group was(22.30±4.22)mmHg,significantly lower than that(29.80±5.59)mmHg of the control group with statistical significance(P<0.05).The PaO2of the experimental group was(82.30±4.43)mmHg,significantly higher than that(70.20±5.22)mmHg of the control group with statistical significance(P<0.05).The angiotensin II of the experimental group was(93.65±5.20)pg/mL,there was no significant significance between the control group and the experimental group.Conclusion The therapeutic effect of Losartan on chronic pulmonary heart disease is ideal,could significantly reduce pulmonary artery pressure and dilation of blood vessels.

关 键 词：洛沙坦 慢性肺心病 肺动脉高压 

分 类 号：R563.3[医药卫生—呼吸系统]